Oppenheimer Discouraged on Teva’s Ability to Generate Gains in the Short-Term


Is Teva Pharmaceutical (NYSE:TEVA) overpriced? For a company that just released a third quarter print, Oppenheimer analyst Derek Archila does not have any sense of improved conviction on the beleaguered biotech giant’s growth arc.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts